Outcome and death risk of diabetes patients with Covid-19 receiving pre-hospital and in-hospital metformin therapies

BackgroundCOVID-19 has stroke Brazil harshly, deaths by COVID-19 in Brazil represent almost 13% of the total deaths by COVID-19 in the world, even though Brazilian population represents only 2.6% of the world population. Our aim in this study was to evaluate death and intubation outcomes and risk factors associated with COVID-19, and treatment options focusing on diabetes patients and the use of metformin pre-admission and during hospitalization.MethodsIn this Brazilian single-center study we evaluated 1170 patients hospitalized due to COVID-19. Diabetes patients (n=188) were divided based on their use of pre-hospital and in-hospital metformin (non-met-group and met-group).ResultsIn the total cohort most comorbidities were risk factors for orotracheal intubation and death. The use of chloroquine/hydroxychloroquine was significantly associated with increased death and intubation risk in uni- and multivariate analysis. Diabetes patients showed worst clinical feature compared with non-diabetes patients. In-hospital non-met-group had increased mortality (20.5%) compared to met-group (3.5%) (p=0.0002) and univariable cox proportion hazard regression indicated in-hospital metformin reduced mortality (HR=0.325, p=0.035). Patients that used pre-hospital metformin showed lower severity parameters at hospital admission. (met-group: 2.452.5; non-met-group: 4.25 +/- 3.4). In all the groups older patients showed more severe clinical conditions and high risk of death and intubation.ConclusionEven though this is a single-center study, results from other reports have shown a similar trend, indicating that patients that used metformin during hospitalization have a better prognosis and reduced risk of death.